Either a hot water bath or a blood warmer attached to an infusion pump may be used to warm up blood donated from patients with cold agglutinin disease (CAD) in order to minimize the risk of agglutination, or blood cell clumping, in a subsequent stem cell transplant, a study…
The case of a man with cold agglutinin disease (CAD) that was found to be secondary to a blood cancer, called diffuse large B-cell lymphoma (DLBCL), was described in a recent report. The researcher proposes that DLBCL should be considered as a potential diagnosis in people with unexplained CAD.
The case of a man with cold agglutinin disease (CAD) co-occurring with a blood cell disorder called myelodysplastic syndrome was described in a recent report from India. The report, “Cold autoimmune hemolytic anemia with myelodysplastic syndrome: Not just an ‘Open and Shut case,” was published in…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…
Mortality rates are generally higher among people with cold agglutinin disease (CAD) and related conditions than in the general population, according to a recent study from Denmark. These results highlight the need for better care for people with CAD, its authors noted. The study, “Survival in…
A case of cold agglutinin disease (CAD) secondary to bacterial infection in a young woman in the U.K. was initially mistaken for blood cancer, according to a recent report. The researchers noted that the 27-year-old patient had severe hemolytic anemia, a condition in which red blood cells are…
COVID-19 can worsen symptoms of cold agglutinin disease (CAD), a recent case report highlights. The scientists stressed the need for further research to determine the best ways to care for people with new or worsening CAD that develops in the context of a COVID-19 infection. In this case, treatment…
The U.S. Food and Drug Administration (FDA) has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusions due to hemolysis, or red blood cell destruction, in adults with cold agglutinin disease (CAD). Enjaymo, which works by preventing hemolysis, is the first and only FDA-approved therapy…
A bone marrow biopsy may be useful as a test for an underlying cancer or other conditions involving the excessive immune cell expansion and guiding treatment in people with newly diagnosed cold agglutinin disease (CAD), according to a new study. The study, “The Role of a…
People with cold agglutinin disease (CAD) show signs of red blood cell destruction year round, not just when the weather is cold, a new study highlights. These findings suggest that CAD patients should be closely monitored at all times, regardless of season, according to researchers. The study, “…
Get regular updates to your inbox.